



Life Settlement Assets PLC – Ordinary Share A

Investment Objective

The company's investment objective is to achieve capital appreciation by purchasing policies or portfolios of life settlement and mortality-related products in special or distressed situations.

Estimated Performance



Commentary

Investment Terms

1.5% Management Fee

Estimated NAV (USD) 93 018 518

NAV/Share 2.1274

from the marketplace are likely to be submitted. The Share Class is reporting a performance of 0.12% for the month of March. Eight HIV maturities were registered, contributing a total Death Benefit of \$0.6M; two maturities of \$1.3M were registered in the non-HIV segment this month.

The pandemic has had a substantial impact on just about every business enterprise, including the life settlement. Many people that were ready to sell their policy prior to the pandemic have decided to wait just in case they became ill. Investors, however, continued seeking policies to buy, creating a sellers' market due to the demand exceeding the limited supply of policies. This has driven up the prices for policies on the life settlement market. But

that pricing phenomenon is likely to change in the not-too-distant future as a


wave of policies is about to hit the market. As more people become fully vaccinated and the virus threat diminishes, policies that had been withheld

Number Of Policies		Death Benefits (USD)	Matured Policies	YTD	Maturities YTD (USD)
4 411		443 818 967	40		16 499 649
Trust Investment Manager	Acheron Capital Ltd.		Company Secretary	ISCA Administration Services Limited	
Administrator	Compagnie Européenne de Révision		ISIN Ticker	GB00BF1Q4B05 LSAA	
Auditor	BDO UK LLP		Info	life@ache +44 207 2	eroncapital.com 158 5990


March 2021









Distribution By Gender



Distribution by Issue Date⁽²⁾ (Yrs)




Maturities Since Inception



(1)Indicates the available face amount to LSA which is a fractional interest of initial face amount.
(2)Distribution by issue dates reflects the time since the life insurance policy was issued.
Source of Data: Acheron Capital Ltd unless otherwise stated.


Distribution by Insurance Company



March 2021








Maturities March 2021

Number of policies matured in March 2021	10
Corresponding number of insured	9
Total death benefit in March 2021 (US\$)	1 951 388
Valuation of Matured policies in Book (US\$)	116 697



Top 10 Coverage

6.5

5.0

4.1

3.6

34

3.0

2.7

2.3

2.2

1.8

Total Face Age

(millions) (ALB)

95

78

96

92

80

94

100

98

99

81

Premiums Situation (US\$)⁽¹⁾

Servicers Premiums Projection for the next 12 months	\$ 12.2M	
Mortality Adjusted Premiums Projection for the next 12 months	\$ 11.6M	
Estimated COI Net of Mortality for the next 12 months	\$ 10.5M	

Cash Situation (US\$)⁽¹⁾

	Cash at hand and similar	\$ 5.8M
Age* 100/120 /100/100	Gross Cash in Policies ⁽²⁾ (estimated as of end 2020)	\$ 49.3M
100 /100/100	Loan on Cash in Policies (estimated as of end 2020)	\$ 14.0M
100 100 120	Net Cash in Policies ⁽²⁾ (estimated as of end 2020)	\$ 35.3M
100/100 100/100	Maturities to be received	\$ 17.9M
100/100		

(1) Figures as provided by third parties

Face (millions)

1.6/0.9/0.6/0.4/0.1

5.3/1.2

4.1

3.4

3.0

2.7

1.3/1.0

1.3/0.9

1.0/0.8

1.8/1.7/1.5

Insured

1

2

3

4

5

6

7 8

9

10

(2) Cash in a policy can typically be borrowed at an interest rate of 4% to 8%. Cash for ABC policies not included. Surrender charge included.

*In case that one insured has more than one policy, their expiration ages are ordered by decreasing face.

Issued by Acheron Capital Limited, a company registered in England, no. 05588630 at Suite1, 3rd Floor, 11-12 St. James's Square, London SW1Y 4LB, England.

Expiration Age*

100/100/100/100/10

121/100/10

Acheron Capital Limited is authorized and regulated by the Financial Conduct Authority ("FCA") and appears on the FS Register under FRN 443685.

The investment products and services of Acheron Capital Limited are only available to professional clients and eligible counterparties; they are not available to retail clients. This document does not constitute an offer to buy or sell shares or units in any fund or funds managed or advised by Acheron Capital Limited. The prospectus of the funds is the only authorized document for offering shares or units in the funds. The prospectus may only be distributed in accordance with the laws and regulations of each appropriate jurisdiction in which any potential investor resides. Investors are also reminded that past performance should not be seen as an indication of future performance and that they may not get back the amount originally invested. UK Investors do not benefit from the Financial Services Compensation Scheme (FSCS). Investment in the funds carry risks which are more fully described in the prospectus. The funds are only suitable for sophisticated investors who are aware of the risks of investing in hedge funds.